IDH3A and glioblastoma: Glioblastoma, isocitrate dehydrogenase (IDH)-wild-type, is the most frequent and the most aggressive type of primary brain cancer in adults, accounting for 48.6% of all malignant tumors within the central nervous system.1The overall annual incidence is 3.23 per 100,000 persons, which further increases with age and is higher in males compared to females.1, 2The median expected survival time is 14.6 months despite extensive treatment,3with less than 5% of glioblastoma patients showing a survival rate of 5 years or more.4, 5